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Abstract
Background: Heparin affin regulatory peptide (HARP), also called pleiotrophin, is a heparin-binding, secreted factor
that is overexpressed in several tumours and associated to tumour growth, angiogenesis and metastasis. The C-
terminus part of HARP composed of amino acids 111 to 136 is particularly involved in its biological activities and
we previously established that a synthetic peptide composed of the same amino acids (P111-136) was capable of
inhibiting the biological activities of HARP. Here we evaluate the ability of P111-136 to inhibit in vitro and in vivo
the growth of a human tumour cell line PC-3 which possess an HARP autocrine loop.
Methods: A total lysate of PC-3 cells was incubated with biotinylated P111-136 and pulled down for the presence
of the HARP receptors in Western blot. In vitro, the P111-136 effect on HARP autocrine loop in PC-3 cells was
determined by colony formation in soft agar. In vivo, PC-3 cells were inoculated in the flank of athymic nude mice.
Animals were treated with P111-136 (5 mg/kg/day) for 25 days. Tumour volume was evaluated during the
treatment. After the animal sacrifice, the tumour apoptosis and associated angiogenesis were evaluated by
immunohistochemistry. In vivo anti-angiogenic effect was confirmed using a mouse Matrigel™ plug assay.
Results: Using pull down experiments, we identified the HARP receptors RPTPb/ζ, ALK and nucleolin as P111-136
binding proteins. In vitro, P111-136 inhibits dose-dependently PC-3 cell colony formation. Treatment with P111-136
inhibits significantly the PC-3 tumour growth in the xenograft model as well as tumour angiogenesis. The
angiostatic effect of P111-136 on HARP was also confirmed using an in vivo Matrigel™ plug assay in mice
Conclusions: Our results demonstrate that P111-136 strongly inhibits the mitogenic effect of HARP on in vitro and
in vivo growth of PC-3 cells. This inhibition could be linked to a direct or indirect binding of this peptide to the
HARP receptors (ALK, RPTPb/ζ, nucleolin). In vivo, the P111-136 treatment significantly inhibits both the PC-3
tumour growth and the associated angiogenesis. Thus, P111-136 may be considered as an interesting
pharmacological tool to interfere with tumour growth that has now to be evaluated in other cancer types.
Background
Prostate cancer is among the leading malignancies in
men throughout much of the industrialized world and
ranks second among causes of death from cancer. The
lack of not enough effective treatments indicates a need
to develop novel treatment strategies targeting new
molecules like growth factors. Epithelial-stromal interac-
tions play a pivotal role in the functional integrity of the
normal prostate adult gland [1]. This physiological pro-
cess requires complex interactions between peptide
growth factors and growth modulators, which may be
regulated either by androgens or by other factors [2,3].
Any imbalance in these interactions, such as up or
down regulation of growth factors or their receptors or
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growth-factor pathways leadst op r o s t a t et u m o u rp r o -
gression. Among the growth-factor families involved in
prostate-cancer progression, Transforming Growth Fac-
tor-beta (TGFb), Fibroblast Growth Factors (FGFs), Epi-
dermal Growth Factor (EGF) and heparin affin
regulatory peptide (HARP) were reported to play a pro-
minent role [3]. HARP, also called pleiotrophin is a 136
amino acids secreted polypeptide that forms with the
p r o t e i nm i d k i n e( M K )as p e c i f i cf a m i l ya m o n gt h e
heparin-binding growth factors [4]. During embryonic
development, HARP is expressed in tissues originating
in the mesoderm and neuroectoderm, suggesting a role
in epithelium-mesenchyme interactions and in neuronal
migration. In adults, HARP expression is limited except
at sites such as the mammary gland and uterus asso-
ciated with reproductive angiogenesis [2]. Furthermore,
HARP overexpression has been documented in patholo-
gies associated with cell proliferation and angiogenesis,
such as rheumatoid arthritis [5] and tumour growth [6].
HARP has been shown to exert oncogenic potential by
transforming various cell lines upon HARP cDNA trans-
fection [7,8]. In addition, HARP has been shown to play
a key role in prostate cancer. Thus, plasma HARP levels
were elevated in patients with prostate cancer [9,10].
Furthermore, HARP protein was associated with epithe-
lial cells in prostate cancer but not in normal prostate
tissue and the mRNAs were located in the stromal com-
partment, suggesting a paracrine mechanism of action
for HARP [11]. In vitro, HARP overexpression in normal
prostate epithelial PNT-1A cells induced both ancho-
rage-independent and anchorage-dependent growth at
low serum concentrations. HARP was also mitogenic for
PC-3, LNCaP, and DU145 cell lines [11]. The growth-
promoting effect of HARP on prostate cancer cells was
also confirmed using an antisense strategy, which estab-
lished HARP as an important autocrine growth factor
for the LNCaP prostate-cancer cell line and as a para-
crine factor involved in angiogenesis [12].
Two transmembrane proteins with intracellular cataly-
tic domains have been described as HARP receptors: the
receptor-type protein tyrosine phosphatase beta/zeta
(RPTP b/ζ) and the anaplastic lymphoma kinase (ALK)
receptor. The mitogenic and anti-apoptotic activities of
HARP were initially linked to the high-affinity tyrosine
kinase receptor ALK in a process mediated by the phos-
phatidylinositol 3-kinase and MAP kinase signaling
pathways [13]. ALK was first identified as a constitu-
tively active, oncogenic, chimeric nucleophosmin-ALK
fusion protein [14]. Like HARP, ALK is expressed dur-
ing normal embryonic development in the similar pat-
tern [15]; however it is also overexpressed in different
several human cancers [16,17]. The neurite outgrowth,
the cell migration and adhesion activities of HARP were
initially associated with the chondroitin sulfate proteo-
glycan RPTP b/ζ [18,19]. HARP was shown to signal
through enforced dimerization of RPTPb/ζ which, in
turn, results in a loss of the RPTPb/ζ catalytic tyrosine
phosphatase activity. Inactivation of RPTPb/ζ by HARP
interaction increased tyrosine phosphorylation of each
of the substrates of RPTPb/ζ leading to modification of
the cytoskeleton network via the b-catenin, p190Rho-
GAP, and b-adducin signaling pathway [20-23]. How-
ever, it has also been recently demonstrated that ALK is
activated through the HARP/RPTP b/ζ pathway, thus
introducing a unique “alternative mechanism of tyrosine
kinase receptor activation” [24].
HARP consists of two beta-sheet domains (N- and C-
TSR) containing thrombospondin-I repeats, which are
flanked by flexible lysine-rich N- and C-terminal tails.
Previous studies suggested that the C-TSR domain and
the C-terminus regions of HARP were particularly
involved in the biological activities of HARP [25-28].
Thus, the C-terminus, composed of amino acids 111
through 136, was involved in the binding of HARP to
the ALK receptor [25,26]. In these previous studies,
mutant HARP protein lacking amino acids 111 through
136 acted as a dominant negative effector of HARP
mitogenic, angiogenic, and transforming activities. The
synthetic peptide composed of the deleted amino-acid
segment P111-136 inhibited HARP mitogenic activity in
NIH-3T3, the growth of MDA-MB 231 cells in soft agar
and competed with HARP for binding to the extracellu-
lar domain of ALK receptor [26] thus representing an
interesting pharmacological tool.
The objective of this study was to further complete
our investigations on P111-136 and to evaluate its
growth inhibitory activity both in vitro and in vivo on
the human prostatic adenocarcinoma cell line PC-3.
Methods
Materials
Culture mediums, foetal calf serum (FCS), G418 and
rabbit antibody to human ALK were supplied by Invitro-
gen (Cergy Pontoise, France). Heparin-Sepharose, strep-
tavidin-Sepharoseg e l sa n dM o n o - S ™ column were
from GE HealthCare (Orsay, France), BM ChemiLumi-
nescence from Roche Diagnostic (Meylan, France).
Superblocker™ solution was purchased from Perbio-
Pierce (Montluçon, France). Immobilon-P from Milli-
pore Corp (Saint-Quentin en Yvelines, France). Goat
antibody to human HARP and rabbit antibody to
human RPTPb/ζ were from R&D (Lille, France). Mono-
clonal antibody to human nucleolin was from Santa
Cruz biotechnology (Montrouge, France), goat anti-
mouse CD31 (PECAM) polyclonal antibody and Matri-
gel™ were from BD Pharmingen Biosciences (le Pont de
Claix, France). Horseradish peroxidase-conjugated rabbit
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Page 2 of 12anti-goat IgG and goat anti-rabbit IgG were purchased
from Jackson (Montluçon, France). Taxol
® was pur-
shased from Sigma Aldrich (Saint Quentin Fallavier,
France). Synthetic P111-136 (KLTKPKPQAESKKKKKE
GKKQEKMLD) and biotinylated P111-136 (KLTKPKP
QAESKKKKKEGKKQEKMLDK-biot-CONH2) were
obtained from Altergen (Schiltigheim, France). Recombi-
nant human HARP was produced and purified from
mammalian culture as described previously [25].
Colony formation in soft agar
PC-3 cells (ATCC, Manassas, VA, USA) were seeded at a
density of 2 × 10
4 in triplicate into 12-well plates contain-
ing agar and DMEM supplemented with 5% FCS and var-
ious concentrations of either P111-136 peptide or anti-
human HARP antibody or control non immune immuno-
globulins. The compounds were added to the culture med-
ium twice a week. After 12 days, colonies larger than 50
μm in diameter were counted using a phase-contrast
microscope equipped with a reticule, in five fields in each
of three wells. The assay was repeated at least twice.
Pull down and Western blot analysis
Cells were cultured in 100 mm Petri dishes in complete
medium, then media were discarded and cells were washed
3 times with ice-cold PBS and lysed with 1 ml of lysis buf-
fer (50 mM HEPES, pH 7, 150 mM NaCl, 10 mM EDTA,
1% TritonX-100, 1% Nonidet P-40 (both v/v), 1 mM phe-
nylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 5
μg/ml aprotinin, and 5 μg/ml leupeptin). For pull down
experiments, total proteins from cell lysate were precleaned
with streptavidin-Sepharose beads for 1 h at room tem-
perature followed by centrifugation at 10,000 × g for 5
min. The beads were collected by centrifugation and the
supernatants were transferred to new microfuge tubes.
After this precleaning step, supernatants were incubated
overnight at 4°C with 5 μM of biotinylated P111-136. A
suspension of streptavidin-agarose beads in a volume of 80
μl was added. After 3 h incubation at 4 °C, beads and
bound proteins were collected by centrifugation (10,000 ×
g, 4°C) and washed by centrifugation three times with ice-
cold cell lysis buffer. The pellet was resuspended in 60 μl
of 2 × SDS loading buffer (100 mM Tris-HCl, pH 6.8, 4%
sodium dodecyl sulfate (w/v), 0.2% (w/v) bromophenol
blue, 20% glycerol, 0.1 M dithiothreitol), and kept at 4 °C
until use. Western blot experiments were performed as
described previously [29] using either anti RPTPb/ζ,a n t i
ALK or anti nucleolin antibodies. For the presence of
HARP in PC-3 conditioned media, experiments were per-
formed as described in previous studies [25].
Tumour-cell inoculation to nude mice
All in vivo experiments were approved by the appropri-
ate ethics committee and conducted in compliance with
European Community directives. PC-3 carcinoma cells
(2 × 10
6) were injected subcutaneously in the right flank
of female athymic nude mice (Janvier, Le Genest St Isle,
France). Two weeks after the injection, mouse had one
palpable tumour about 60 mm
3 in size. Groups of 5
mice were then given peritumoral injections of either
0.1 ml PBS alone, Taxol
® 10 mg/kg twice a week, or
P111-136 (5 mg/kg/day). Tumour size was determined
twice a week by using callipers to measure the lengths
of the two main axes, computing the corresponding
radii (labelled R1 and R2, with R1 < R2), and estimating
tumour volume as V = 4/3 × π ×R 1
2xR2,w h e r eR 1 is
radius 1, R2 is radius 2 and R1 <R 2.
Tissue preparation, immunohistochemical staining, and
image analysis
The PC-3 tumours were removed surgically then
immediately quick-frozen in liquid nitrogen and fixed
for 20 min in acetone at 4°C. The 6-μms e c t i o n sw e r e
rehydrated in PBS then saturated with PBS containing
1% bovine serum albumin (BSA) and 2% normal goat
serum. Endogenous biotin was blocked using the Vec-
tor blocking kit (Vector Laboratories, Burlingame,
CA). To visualize endothelial cells within the tumours,
sections were incubated with goat anti-mouse CD31
polyclonal antibody for 1 h at room temperature.
After two washes in PBS-Tween 20 (0.2% v/v), sec-
tions were incubated for 1 h at room temperature
with biotinylated goat anti-rabbit IgG (Chemicon
International Inc., Temecula, CA) in saturation buffer,
followed by three washes and incubation with an avi-
din-biotinylated-alkaline phosphatase complex (Vector
Laboratories). Alkaline phosphatase activity was
revealed using the Vector red substrate (Vector
Laboratories). Finally, the sections were counter-
stained with haematoxylin, washed with water, and
cover slipped with mounting medium (Thermo Shan-
don, Pittsburgh, PA). For each CD31-labelled section,
five microscopic fields containing exclusively viable
tumour cells were randomly selected for analysis.
Endothelial-cell density was expressed as the ratio of
endothelial-cell area/total area examined × 100. Mean
values were then computed for untreated and treated
tumours.
For tumour apoptosis analysis, immunohistochemistry
was performed as previously described [30] using rabbit
antibody raised against cleaved caspase 3 (Cell Signaling
Technology, Saint-Quentin en Yvelines, France). Quanti-
fication of staining on histological slides was achieved
using PIXCYT; a software package [31] designed by the
Groupe Régional d’Etudes sur le Cancer, (Centre Fran-
çois Baclesse, Caen, France). This system combines a
dedicated slide scanner and a computer-assisted image
analysis.
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Page 3 of 12In vivo mouse angiogenesis assay using the Matrigel™
plug model
Swiss mice (Janvier, Le Genest St Isle, France) were
injected subcutaneously with 0.3 ml of growth-factor
reduced Matrigel™ alone or containing either P111-136
(1 μM), HARP (5 nM), or a mixture of HARP and
P111-136, (4 mice/group). The Matrigel™ rapidly
formed a single, solid, gel plug. After 8 days, the skin
was pulled back to expose the intact plug, which was
dissected out, frozen in liquid nitrogen, and fixed with
acetone. Matrigel™ plug sections 8 μmi nt h i c k n e s s
were cut using a cryostat CM3050 (Leica Microsystems,
Rueil, France) and stained with Gomori-Trichrome for
microscopic observation. The area infiltrated by
endothelial cells was then measured using an image ana-
lyser in six fields in each of three Matrigel™ plug sec-
tions from each mouse.
Statistical analysis
Unpaired Student’stt e s tw a su s e dt oa s s e s sd i f f e r e n c e s
between each group and the corresponding control
group. Each experiment includes triplicate measure-
ments for each condition. All results are reported as
mean ± SD determined from at least two independent
experiments.
Results
Previously, it has been shown that peptide P111-136,
structurally related to the C-terminal domain of HARP,
inhibited specifically the mitogenic activity induced by
HARP. It was also shown that P111-136 inhibited the in
vitro growth of the human breast cancer cell line MDA-
MB 231 suggesting that P111-136 blocked the autocrine
stimulation loop of HARP. In order to investigate more
precisely the effect of P111-136 on tumour growth,
including in vivo study, we investigated the effect of
P111-136 on the androgen-independent prostate-cancer
cell line PC-3 in which the presence of an autocrine
loop of stimulation for this growth factor has been sug-
gested [11,32].
The peptide P111-136 inhibits the growth of PC-3 cells
To confirm the HARP autocrine loop in supporting the
growth of PC-3 cells, the presence of HARP in the
conditioned media of PC-3 was firstly investigated by
Western-blot. As shown in Figure 1A, a weak immunor-
eactive signal was observed in accord with previous
observations [32]. Secondly, to prove that secreted
HARP acted on PC-3 cells, the growth of these cells was
studied in the soft agar colony-formation assay, a hall-
mark of malignant transformation, in absence or pre-
sence of a polyclonal anti-HARP antibody. As presented
in Figure 1B, the polyclonal anti-HARP antibody
induced a dose-dependent decrease in colony formation,
whereas no effect has been observed using the idiotypic
immunoglobulins as the control. These data confirmed
the existence of an autocrine HARP-signalling loop for
PC-3 cells and prompted us to investigate the effect of
P111-136 on the proliferation of this cell line. P111-136
dose-dependently decreased colony formation (Figure
1 C ) .I nt h ep r e s e n c eo f1μM P111-136, the colonies
were smaller and 47% less numerous, compared to the
control performed without peptide. In this respect, it is
noteworthy that when tested in the same conditions,
P122-131, which is another peptide derived from the C-
terminal part of HARP inhibiting the growth of DU145
and LNCap prostate cancer cells [33], acted also on PC-
3 cells but in a lesser extent with only 22% inhibition
for 1 μM (data not shown).
The peptide 111-136 inhibits the tumour growth of PC-3
cells in a mice xenograft model and the associated
angiogenesis
To further investigate the effect of P111-136 on HARP-
induced PC-3 proliferation in vivo, athymic mice were
subcutaneously injected with PC-3 cells, which consis-
tently led to tumour development within 2 weeks. P111-
136 treatment was initiated at the end of the second
week, when the tumours were well established, in order
to simulate a curative treatment. Peritumoral injection
of P111-136 (5 mg/kg/day) significantly reduced tumour
growth as soon as the first week of treatment, compared
to PBS used as the control (Figure 2A). After 25 days,
tumour size was reduced by 61% in the P111-136 group.
P111-136 treatment had no effect on body weight (data
not shown) and induced no evidence of toxicity such as
diarrhoea, infection, weakness, or lethargy. As expected,
control treatment with Taxol
® (10 mg/kg twice a week)
strongly inhibited tumour growth, by 71% compared to
PBS, after 25 days of treatment (Figure 2A). At the end
of the study, the animals were sacrificed and tumour
weight was determined. Both P111-136 and Taxol
® sig-
nificantly decreased tumour weight, by more than 65%,
compared with PBS, supporting the tumour-size data
(Figure 2B). In order to investigate whether P111-136
treatment was associated with apoptosis of PC-3 cells,
cleaved caspase 3 immunostaining was performed on
tumour sections and quantified by software analysis. As
shown in Figure 3, a two-fold increase in cleaved cas-
pase 3 labelling was observed in tumour treated with
P111-136 compare to the untreated tumours. In third
investigation, to determine whether angiogenesis asso-
ciated with tumour growth was also affected by P111-
136 treatment, we used CD31 immunostaining to quan-
tify blood vessels. Compared to the untreated tumours
(Figure 4A and 4C), peritumoral injections of P111-136
significantly decreased endothelial-cell density (Figure
4B and 4C). The mean percentage of endothelial cells in
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P111-136 was inhibited by 64% compared to the control
tumour value (1.7 ± 0.58 vs. 4.8 ± 2, based on 25 fields
in each of four tumours). These results suggested that
the antitumoral effect of P111-136 could also act
through direct inhibition of angiogenesis.
The peptide P111-136 inhibits the in vivo HARP-induced
angiogenesis in a Matrigel™ plug model
To investigate a direct effect of P111-136 on angiogen-
esis processes, we questioned whether the peptide inhi-
bits the normal angiogenesis induced by HARP. This
study was performed using in vivo mouse Matrigel™
plug assay. Incorporating 5 nM of HARP into the Matri-
gel™ resulted in a 3.7-fold increase in endothelial-cell
infiltration (Figure 5C and 5E) compared to the
untreated control plug, which contained only a few
endothelial cells (Figure 5A and 5E). Addition of 1 μM
of P111-136 to the HARP-containing Matrigel™
inhibited the effect of HARP on endothelial cell infiltra-
tion by 72% (Figure 5C, D and 5E). P111-136 had no
effect on endothelial-cell infiltration using Matrigel™
alone (Figure 5A, B and 5E). These data indicate that
P111-136 inhibited the angiogenesis induced by HARP.
P111-136 targets HARP interacting proteins
Since P111-136 was previously described to compete
with HARP for the binding of the ALK receptor [26] in
ac e l lf r e ea s s a y ,w et h e nq u e s t i o n e dw h e t h e rP 1 1 1 - 1 3 6
could bind in situ, using PC-3 cells, ALK and also the
other molecular targets involved in the biological activity
of HARP including RPTPb/ζ and nucleolin [34]. Pull-
down experiments using biotinylated P111-136 (biot-
P111-136) and Western blot analysis were performed to
answer this question. Firstly, Western blot analysis per-
formed from whole-cell extracts of PC-3 indicated that
this cell line expressed the 140 and 220 kDa forms of
ALK (Figure 6A), only the 240 kDa form of RPTPb/ζ
Figure 1 Inhibition of PC-3 colony formation by peptide P111-136 and association with the HARP receptors. (A), Western blot analysis of
HARP in the conditioned media of PC-3 cells (PC-3), 20 ng of recombinant HARP was used as reference. (B), polyclonal anti-human HARP
antibody or control IgG or (C), P111-136 peptide were added to the culture medium twice a week. After 12 days, colonies with diameters
greater than 50 μm were identified using a phase-contrast microscope equipped with a reticule. Representative pictures of colonies are shown
below each treatment. Scale bar, 100 μm. Asterisks denote statistically significant differences with the corresponding untreated cells. Data are the
means +/- SD of two experiments, each carried out in triplicate. *0.01 <p < 0.1, **0.001 <p < 0.01, and *** p < 0.001.
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Page 5 of 12Figure 2 Inhibition of tumour growth by peptide P111-136. (A), Tumour-growth curves. PC-3 carcinoma cells (2 × 10
6) were injected
subcutaneously into the right flanks of female nude mice. When tumour size was about 60 mm
3, mice received peritumoral injections of P111-
136 (5 mg/kg/day) (black circle), Taxol
® (10 mg/kg twice a week) (white circle), or PBS used as vehicle. (black square) for 25 days. Tumours were
measured twice a week. (B), The mice were sacrificed 25 days after the cell injection; the tumours were excised and weighed. (C), A
representative excised tumour of each group was represented below. Scale bar, 1 cm. The data are mean tumour volume or weight +/- SD
obtained from 5 mice in each group. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control (untreated tumours).
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Page 6 of 12Figure 3 Induction of apoptosis in xenograft tumour by P111-
136. PC-3 tumour apoptosis was evaluated on tumour sections
using immunohistochemistry with antibody directed against cleaved
caspase 3. (A), untreated tumours and (B), tumours treated with
P111-136. Scale bar, 100 μm. (C), apoptosis quantified by image
analysis of caspase 3-labelled cells on the whole tumour sections.
The data are mean areas +/- SD obtained from 5 control mice and
5 mice treated with P111-136. **p < 0.01 versus control.
Figure 4 Inhibition of tumour angiogenesis by peptide P111-
136. For immunohistochemical analysis, tumour sections were
prepared and stained with anti-CD31 antibodies. (A), untreated
tumours and (B), tumours treated with P111-136. Scale bar, 100 μm.
(C), angiogenesis was quantified by image analysis of CD31-labelled
endothelial cells. The data are mean areas +/- SD obtained from 5
control mice and 5 mice treated with P111-136. **p < 0.01 versus
control.
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Page 7 of 12(Figure 6B) and the 100 kDa nucleolin and its degrada-
tion products (Figure 6C), as previously described [35].
For expression of ALK and RPTPb/ζ,U 8 7M Ga n d
DU145 cell lysates were used respectively as control
(Figure 6A and 6B). These different HARP interacting
proteins were also detected in biot-P111-136 pull down
experiments (Figure 6A, B and 6C) in which these pro-
teins were identified by Western blot analysis while no
band was detected when bio-P111-136 was omitted
from the assay. It is noteworthy that only the 140 kDa
isoform of ALK was detected in the biot-P111-136 pull
down (Figure 6A). All together these results demon-
strate that the inhibition of PC-3 proliferation observed
with P111-136 could be link to a direct or indirect bind-
ing of this peptide to the different HARP interacting
proteins.
Discussion
HARP is expressed in a wide range of tumour cell lines
including neuroblastoma, glioblastoma, melanoma and
also of cancers derived from the pancreas, breast, and
prostate [8,10,11,36-38]. Numerous studies using ribo-
zyme, RNA interference or antisense strategies
[12,38-41] showed that HARP was a potential in vivo
rate-limiting angiogenic factor in tumour growth and
metastasis. As a result, HARP and its two signalling
receptors ALK and RPTPb/ζ are now viewed as promis-
ing targets for cancer therapy [17,38,39,42,43]. Using
recombinant deletion mutant of HARP, we previously
established that the HARP C-terminus domain, com-
posed of amino acids 111 to 136, was closely involved in
the mitogenic, angiogenic and transforming activities of
HARP [25,26]. Thus, the synthetic peptide P111-136 has
been shown to bind to the ALK receptor, thereby acting
as a dominant inhibitor of the biological activities of
HARP. These findings, together with the key role for
HARP in prostate-tumour growth, prompted us to
further investigate the potential anti-tumour effects of
P111-136, using the human androgen-independent ade-
nocarcinoma PC-3 cell line, which expressed HARP and
its receptors [11].
In the in vitro experiments reported here, P111-136
inhibited the growth of PC-3 cells. Using whole-cell
lysate from PC-3 cells, pull-down experiments with bio-
tinylated P111-136 indicated that P111-136 interact, as
expected, with ALK and also with RPTPb/ζ suggesting
that this peptide might bind also to the RPTPb/ζ recep-
tor. This hypothesis is strengthen by the recent data
showing that synthetic peptide including amino acids
122 to 131 derived from the C-terminus region of
HARP binds to RPTPb/ζ [29]. Recently Diamantopoulou
et al [33] have demonstrated that this shorter peptide
P122-131 was able to inhibit the proliferation of other
human prostate cancer cell lines DU145 and LNCaP. It
is interesting to mention that these cell lines do not
express the ALK receptor (Additional file 1, Figure S1).
However, when tested in our conditions, P122-131
inhibited only the anchorage independent growth of PC-
3 cells by 22% at 1 μM when compare to 47% for P111-
136. The presence of the ALK receptor in PC-3 cells
could explain this difference of efficiency between the
two peptides but further investigations of both peptides
Figure 5 Inhibition of HARP-induced in vivo angiogenesis by
peptide P111-136. Liquid Matrigel™ at 4°C was injected
subcutaneously into Swiss mice. The Matrigel™ was used alone or
after incorporation of HARP, P111-136, or both. The animals were
sacrificed 8 days later; the Matrigel™ plugs were removed,
sectioned, stained using the Gomori-Trichrome method, and
examined under the microscope. Scale bar, 100 μm. Micrographs of
Gomori-Trichrome stained Matrigel™ plug (A) alone, (B) containing
1 μM of P111-136, (C), containing 5 nM of HARP, or (D) containing 5
nM of HARP and 1 μM of P111-136. (E) endothelial-cell migration
into the Matrigel™ was quantified as the mean cell count in six
fields in each of three Matrigel™ plug sections per mouse, data are
means +/- SD of values in four mice per group. **p < 0.01.
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to clarify this point. When assayed on the human glio-
blastoma cell line U87 MG described previously as
expressing a low level of RPTPb/ζ [44], P111-136 inhib-
ited the colony formation in a lesser extent (data not
shown) supposing that an optimal expression of both
ALK and RPTPb/ζ receptors could be important for a
strong effect of P111-136. Therefore, further investiga-
tions will be needed to verify this assumption. For sev-
eral years, the receptors involved in the growth-
promoting effect of HARP are a matter of controversy
[45] due to the cell system and molecular tools used.
However, it has been clearly demonstrated that the
binding of HARP or its related protein MK to the ALK
receptor activated the intracellular kinase domain and
further stimulated the downstream MAP and PI-3
kinase pathways [13,46,47]. More, recently Stylianou et
al., have also mapped the HARP ligand binding domain
on ALK and found that a single chain antibody was able
to compete for the HARP binding and inhibit its inter-
cellular downstream signal [48]. Other data have
reported that binding of HARP to RPTPb/ζ receptor
Figure 6 Interaction of P111-136 with HARP receptors. Whole PC-3 cell lysates were incubated or not with biot-P111-136 immobilized on
streptavidin-Sepharose beads, or with streptavidin-Sepharose beads alone. The lysates or the precipitates were analyzed by SDS-PAGE and
electroblotted and the membrane was probed against ALK (A), RPTPb/ζ (B) and nucleolin (C) using specific antibodies. U87 MG and DU145 cell
lysates were respectively used as positive controls for the presence of ALK and RPTPb/ζ receptors.
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lar catalytic phosphatase activity, leading to further acti-
vation of the Src/Fyn kinase family and b-catenin
phosphorylation pathway [20,21]. The RPTPb/ζ receptor
was found to be involved in HARP-induced cell migra-
tion and neurite outgrowth [18,19] and was then shown
to play a role in glioblastoma cell proliferation [42,43].
In addition, a recent study [24,42,43] identified an alter-
native mechanism in which binding of HARP to
RPTPb/ζ maintained the phosphorylation of ALK, lead-
ing to further activation of its pathway. The results
described in this study, strongly suggested that a link
between ALK and RPTPb/ζ could occur in PC-3 cells
since P111-136 pulled down both receptors.
Nucleolin, a nuclear and cytoplasmic protein initially
related to rRNA maturation ribosome assembly [49],
was also described as a cell surface protein [35] and as a
low affinity binding protein for HARP [34] and MK
[50,51]. Since nucleolin was clearly identified in our pull
down experiments, it is tempting to suggest that this
protein could also be implicated in the HARP biological
activities. As support of this hypothesis, we have shown
that anti nucleolin antibody inhibited the biological
activity of HARP in MDA-MB 231 cell line [52]. The
mechanism of this inhibition remains to be studied.
However, previous data have shown that the b-sheet
domains of HARP, especially those located on the C-
terminal part of the molecule, were involved in the
binding of HARP to nucleolin. Since nucleolin was
pulled down by P111-136 in our experiments, we could
speculate that the peptide did not bind directly to
nucleolin but through other non identified molecules,
this possibility is currently under evaluation.
The strong inhibition of P111-136 observed on the
growth of PC-3 cells in vitro and their tumour xenograft
in nude mice could be explain because it targets directly
or indirectly different proteins of the HARP pathway.
Furthermore in vivo, the inhibition of tumour growth
was linked with an increase in PC-3 cells apoptosis and
a decreased in the tumour associated angiogenesis. Dur-
ing this treatment, no side effects were observed on
mice suggesting that P111-136 did not present any toxi-
city nor cause additional pathology on animals. Recently
Grzelinski et al., [53] have demonstrated an enhanced
antitumor effect on glioblastoma using a double ribo-
zyme strategy targeting HARP and one of its receptor. It
is tempting to speculate that such results could be
obtained on PC-3 tumours in combining P111-136
treatment with another molecule that target the HARP
pathway.
Evidence that C-terminus maturation influences the
biological effects of HARP was obtained in an earlier
study, in which a 14-kDa C-terminal truncated form of
HARP influenced the proliferation of cells like bovine
epithelial lens cells [54]. Thus, natural processing of the
HARP molecule could be pivotal in regulating the bio-
distribution and biological effects of HARP in health
and disease. In keeping with this possibility, we showed
that plasmin and MMP-2 cleaved HARP in vitro, releas-
ing various peptides that may differentially affect the
angiogenic and mitogenic activities of HARP [55,56].
GAGs in the microenvironment may protect HARP
from this enzymatic cleaving. Thus, the biological effect
of HARP is the net result not only of HARP secretion
and degradation, but also of specific enzymatic proces-
sing, which depends on the proteases and GAGs present
in the microenvironment and may generate peptides
that have diverse (and perhaps opposite) biological
effects.
Conclusions
Our results demonstrate that P111-136 strongly inhibits
the proliferative effect of HARP on in vitro and in vivo
growth of PC-3 cells. This inhibition of P111-136 could
be link to a direct or indirect binding of this peptide to
the different HARP interacting proteins (ALK, RPTPb/ζ,
nucleolin). In vivo, the daily P111-136 treatment was as
effective as the one of a clinical drug used in prostate
cancer therapy. Furthermore the tumour growth inhibi-
tion was associated with an inhibition of angiogenesis
and an increase in PC-3 cells apoptosis. Thus, P111-136
may be considered as an interesting pharmacological
tool to interfere with tumour growth that has now to be
evaluated in other cancer types and animals models.
Additional material
Additional file 1: Expression of the ALK receptor in PC-3, DU145
and LNCap cells. DU145 and LNCaP were cultured in completed
medium as described in Diamantopoulou et al., [33]. Western blot (WB)
and RT-PCR experiments were performed with respectively lysate and
total RNA from PC-3 (positive control), DU145 and LNCaP cells as
described in Dos Santos et al., [28].
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